A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Neurofibromatosis type 1 is a genetic condition, with a 50 per cent likelihood of being passed on if one parent has it. Read ...

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies ...

Please provide your email address to receive an email when new articles are posted on . The researchers were tasked with helping a patient who had a novel form of recalcitrant erythroderma. Using a ...

Palvella Therapeutics, Inc. ( ($PVLA) ) has released its Q3 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented ...

Trinity researchers, along with UK collaborators, have created a simple but powerful diagnostic tool, which they believe will ...

The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal ...

NEW YORK (WPVI) -- The family of a Staten Island teenager with a rare disability received a special gift Wednesday -- a new home. WABC-TV reports, John Hudson Dilgen suffers from a rare skin condition ...

Also check out Saint Louis Chamber Chorus, Voices of Change, "Protest: From Martin Luther to Bob Dylan" on the St. Louis ...